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In France, SCD prevalence tends to be higher in the pop-
ulation of infants born to parents from Sub-Saharan Africa,148  rev bras hematol hem
Description  of  the  method  used  to  gather
evidence
These Guidelines were prepared by elaborating eight clinically
relevant questions, two related to neonatal screening for SCD
and six related to painful vaso-occlusive crisis in SCD. The
questions were structured using the Patient/Problem, Inter-
vention, Comparison and Outcome (PICO) system (Appendix
A), allowing the generation of evidence search strategies in
the key scientiﬁc databases (MEDLINE PubMed, Lilacs, Sci-
ELO, Embase, Cochrane Library, Premedline via OVID). The
data recovered were critically analyzed using discriminatory
instruments (scores) according to the type of evidence – JADAD
for randomized clinical trials and the Newcastle Ottawa scale
for non-randomized studies. After identifying studies that
potentially substantiate recommendations, the level of evi-
dence and degree of recommendation were calculated using
the Oxford Classiﬁcation.1
Degree  of  recommendation  and  level  of
evidence
A: Major experimental and observational studies
B: Minor experimental and observational studies
C: Case reports (non-controlled studies)
D: Opinion without critical evaluation based on consensus,
physiological studies or animal models
Background
SCD is a group of inherited diseases in which the synthesis of
hemoglobin (Hb) is impaired because of a mutation in the beta
globin chain of the Hb gene on chromosome 16. This muta-
tion leads to the substitution of a glutamic acid for valine at
position 6 of the beta chain, resulting in the production of Hb
S whose expression causes sickling of red blood cells, poly-
merizing Hb with resulting vaso-occlusion, pain and chronic
organ damage.1–3 (D) Hb S is the most common abnormal Hb
in Brazil.2 (D)
Sickle cell anemia occurs when the patient is homozygous
for the Hb S gene (Hb SS). Moreover, Hb S can be associ-
ated with other abnormal Hb, such as Hb S/beta-thalassemia,
Hb SC, Hb SD, persistence of Hb fetal (Hb F) with Hb S,
among others. The term SCD deﬁnes both sickle cell ane-
mia  and these associations. The combination of the Hb S
gene with normal Hb (Hb A) characterizes the sickle cell trait
(Hb AS).1–3 (D)
The diagnosis of SCD, a condition with high morbidity and
mortality rates, is made at birth with neonatal screening.
The pathophysiology is complex and evolves with acute and
chronic complications that affect different organs and sys-
tems.
Because of the complexity of SCD, many  questions were
asked during the development of these guidelines and so it
was decided to present them in three parts. The ﬁrst part
discusses diagnosis by neonatal screening and aspects of
vaso-occlusive crisis, the second part answers questions about
splenic sequestration and the central nervous system from 2 0 1 6;3  8(2):147–157
diagnosis to treatment and the third part deals with the
prevention of infections, diagnosis and treatment of fever, pri-
apism and bone marrow transplantation.
Objective
The aim of the ﬁrst part of these guidelines is the approach to
diagnosis by neonatal screening and subsequent conﬁrmation
of SCD and questions related to the diagnosis and treatment
of the vaso-occlusive crisis.
What  is  the  prevalence  of  sickle  cell  disease
and  how  are  the  results  of  neonatal  screening
for hemoglobinopathies  interpreted?
P: All newborn babies
I: Results of neonatal screening
C:
O: Interpretation of the results
The laboratory techniques used to identify hemoglobin
in the Newborn Screening Program are high-performance
liquid chromatography (HPLC) and isoelectric focusing (IEF)
because these tests can quantify small amounts of Hb; the
main Hb in the newborn is Hb F.4–16 (A),17 (B) Several dis-
eases are investigated during neonatal screening, including
SCD, phenylketonuria and congenital hypothyroidism.4–8,12–16
(A) The Hb with the highest concentration is shown
ﬁrst in the neonatal screening results and so Hb F will
always be followed by the other hemoglobins.4–6,14 (A)1–3 (D)
Table 1 shows how to interpret neonatal screening results.
The most common hemoglobinopathies in Brazil are Hb
FAS, Hb FS, Hb FSA, Hb FSC, Hb FSD and Hb FSA + Hb
Bart’s.
The prevalence of Hb S in Brazil is from 1.2 to 10.9% depend-
ing on the region of the country,5,6,13–16 (A),17–19 (B) while the
prevalence of Hb FS (sickle cell anemia) ranges from <0.1
to 0.2%6,7,13–16 (A)17,19 (B) and Hb FSC ranges from <0.1 to
0.9%.5–7,14,15 (A)17,18 (B) It is noteworthy that the states with the
highest number of cases of SCD are Bahia and Rio de Janeiro,
while Paraná and Rio Grande do Sul have the lowest rates.
The prevalence of Hb C is from 0.15 to 7.4%.5–7,14,15 (A)17–19
(B). Hb S/beta-thalassemia has been identiﬁed in the states
of São Paulo, Minas Gerais, Paraná and Rio Grande do Sul, all
with prevalences <0.1%.5,6,14,16 (A) In the city of Ribeirão Preto,
São Paulo the incidence for sickle cell anemia was shown to
be 1:7,358 and for Hb SC disease 1:9,365.7 (A) In Rio Grande
do Sul the incidence of SCD (Hb SS, Hb SC, Hb SD and Hb
S/beta-thalassemia) was 1:9,1206 (A) and in Minas Gerais the
incidences of Hb FS and Hb FSC were 1:2,800 and 1:3,450,
respectively.14 (A)the Mediterranean, the Arabian Peninsula, French islands
and India compared to the general population (3:10,000 vs.
1:10,000).20 (B) In Brazil, the USA and the United Kingdom,
universal screening is considered ideal due to the population
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Table 1 – Interpretation of neonatal screening test for hemoglobinopathies3 (D).
Result Interpretation Clinical condition
FAa Normal Asymptomatic
FAS Sickle cell trait Asymptomatic
FS Sickle cell anemia (Hb SS) or
Hb S/Beta0-thalassemia or
Hb S/HPFH
Hemolytic  anemia
FSA or FSb Hb S/Beta+-thalassemia Hemolytic anemia
FSC Hb SC Hemolytic  anemia
FSD Hb SD Hemolytic  anemia
FSA + Hb Bart’s Hb  S/alpha-thalassemia Hemolytic anemia
FSE Hb SE Hemolytic anemia
FSVc Hb SV Hemolytic anemia
FAC Hb C trait Asymptomatic
FC Hb C or
Hb C/beta0-thalassemia
Hemolytic anemia
FCA Hb C/beta+-thalassemia Hemolytic anemia
FAD Hb D trait Asymptomatic
FD Hb D Hemolytic anemia
FDA Hb D/beta+-thalassemia Hemolytic anemia
FA + Hb Bart’s (1–5%) Silent carrier of
alpha-thalassemia
Asymptomatic
FA + Hb Bart’s (5–10%) Alpha-thalassemia trait Mild anemia
FA + Hb Bart’s (25–50%) Hb H disease Hemolytic anemia
F 0-thalassemia
(thalassemia major) – by
high-performance liquid
chromatography
Hemolytic anemia
HPFH: hereditary persistence of fetal hemoglobin.
a FA because fetal Hb is predominant at birth; the result of thalassemia minor is also Hb FA.
b Hb FSA is Hb S associated with beta-thalassemia. However, if the percentage of Hb A is very low, the phenotype in neonatal screening may
be Hb FS.
c FSV indicates Hb variants different from Hb A, Hb S, Hb C, Hb E, Hb D and Hb Bart’s. The following Hb variants have been identiﬁed in Brazil:
Hb Woodville, Hb Chad, Hb G-Phil, Hb E-Saskatoon, Hb Richmond, Hb O-Arab, Hb Beckman, Hb Hope.
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sharacteristics.4,10 (A),2 (D) Screening is also universal in
elgium.11 (A)
After the diagnosis of SCD, children and their families
hould be provided special care, as there is a possibility of
ther cases of SCD in the family.4,8,11,13,15 (A),21,22 (C)
The interpretation of newborn screening for sickle cell
nemia depends on the initial tests and the conﬁrmation
ethod used. The proper interpretation and use of these
esults depends on the implementation experience of neona-
al screening programs.8 (A)
The Neonatal Screening Program for hemoglobinopathies
n Brazil has had a great impact on SCD mortality and mor-
idity rates, as early diagnosis permits the use of prophylactic
ntibiotic therapy, special vaccinations and the training of par-
nts and caregivers about the clinical characteristics of SCD,
uch as spleen palpation for splenic enlargement.23 (D)
Recommendation: The results of neonatal screening
for hemoglobinopathies should be interpreted based on
tests made using HPLC or IEF. As Hb is expressed in
decreasing order of concentration, HbF will always be the
ﬁrst to be reported in the results, followed by at least one
other Hb.Is  there  evidence  for  the  need  to  perform  a
conﬁrmatory  electrophoresis  exam  after  the
sixth  month  of  life?
P: Over 6-month-old patients and abnormal hemoglobin
results in neonatal screening
I: Blood collection for hemoglobin electrophoresis
C: Results of neonatal screening
O: Interpretation of the results
The diagnosis of hemoglobinopathies needs to be con-
ﬁrmed when the child is about six months old and, in some
situations, a study of the parents or molecular analysis (DNA)
of the child should be made.1,2 (D),4,6–8,10,11,14–16 (A)
Positive results should always be conﬁrmed.4,5,10–12,24 (A)
The combination of methods (IEF and HPLC) reduces the pos-
sibility of false negative results for SCD, which can occur in
cases of red blood cell transfusions prior to sample collec-
tion or prematurity.4,9 (A) False positive results for sickle cell
anemia can be found in the rare combination of Hb S and Hb
Hope detected by IEF. In France, two cases in 42 infants with
suspected Hb SS, actually had Hb S/Hb Hope.25 (B)
A Brazilian study of 4,635 children from Minas Gerais
diagnosed with Hb AS, Hb AC or Hb AD in neonatal
oter.150  rev bras hematol hem
screening showed 0.6% of discordant results between the
initial screening and an IEF exam after six months of life.
Seven cases had had blood transfusions before blood collec-
tion, seven cases had problems in blood collection or in the
transcription of the exam results, there was difﬁculty to dif-
ferentiate between Hb S and Hb D in eight cases and the reason
was not identiﬁed in ﬁve cases.14 (A)
Recommendations: All children identiﬁed as having
hemoglobinopathies during neonatal screening should
be retested by hemoglobin electrophoresis after six
months of life.
Is  there  evidence  on  the  factors  that  cause  a
vaso-occlusive  crisis?
P: Patients between 0 and 18 years old with sickle cell anemia
and painful crisis
I: Fever, dehydration, infection, metabolic disorder, exposure
to extreme cold and heat, alcoholism, osteomyelitis, illegal
drugs (marijuana, cocaine)
C: Without symptoms
O: Triggers of vaso-occlusive crisis
Several factors have been associated with the vaso-
occlusive crisis in patients with SCD, such as infections,
climate change, psychological factors, altitude, acidosis, sleep
apnea, stress, dehydration, hypoxia and physical exhaustion.
However, in most cases the triggering factor is not identiﬁed.26
(D)
Pain crises in these patients have variable intensities
and frequencies, being higher in winter. Higher tempera-
tures during winter were associated with less pain intensity
and frequency.27 (B) However, another study did not conﬁrm
the association between changes in temperature and pain
frequency.28 (B) Moreover, the hospitalization rate for pain cri-
sis increases with the intensity of wind and air humidity.29,30
(B)
Some factors increase the likelihood of hospitalization for
painful crisis in patients with SCD. In a multivariate analysis
of factors associated with crisis, increased risk of hospitaliza-
tion was observed in subjects with Hb SS (hazard ratio: 3.1), in
those exposed to smoking (hazard ratio: 1.9) and those with
a history of asthma (hazard ratio: 1.3).31 (B) Another study
demonstrated the importance of respiratory symptoms and
asthma in pain crisis.32 (B) An assessment of nocturnal O2
saturation and painful crisis in 90 patients with sickle cell ane-
mia  concluded that a nocturnal O2 saturation <90% (p-value
<0.0001), Hb below 8.8 g/dL (p-value <0.01) and a hematocrit
below 28% (p-value <0.0012) are associated with the onset of
symptoms.33 (B)
Other clinical situations are associated with pain crisis in
patients with SCD, including high blood viscosity34 (B) and
menstruation (61.5% of cases of crisis in women occur during
menstruation).35 (C) 2 0 1 6;3  8(2):147–157
Recommendation: Factors associated with pain cri-
sis can be environmental, such as temperature, wind
and humidity or clinical such as respiratory diseases,
increased blood viscosity, anemia and menstruation.
Smoking increases the risk of hospitalization and some
infections increase the risk of having a painful vaso-
occlusive crisis.
Is  there  evidence  that  the  use  of  pain
assessment  scales  is  a  good  method  to  monitor
pain  related  to  vaso-occlusive  crisis?
P: Patients between 0 and 18 years old with sickle cell anemia
and painful crisis
I: Following up treatment using pre-established pain scales
C: Following up treatment without using pre-established
pain scales
O: Adequate pain control
There are several challenges to pain management in sickle
cell anemia, such as disregarding the level of pain felt by
patients, the difﬁculty to ‘quantify’ this pain, the best instru-
ment to assess pain, the discrepancy between pain and patient
behavior, the inadequate prescription of analgesia and the fear
that the patient becomes dependent on opioids. Only by eval-
uating the true intensity of the pain, is it possible to offer the
best treatment.36 (B)
Three methods are used to evaluate pain intensity. The
African-American Oucher scale is designed for children
between 3 and 12 years and gives scores of 0–100 for the
intensity of pain; it consists of a series of pictures of children
expressing different levels of pain. The Wong-Baker FACES
scale uses pain scores between 0 and 5, and can be used in
over 3-year-old children; it is comprised of a series of drawings
of faces expressing different levels of pain. The visual analog
scale (VAS) uses a horizontal 10-cm line on paper, where one
end is designated as no pain and the other is designated as
extreme pain; the patient indicates at what level his/her pain
is on a scale of 0–10.37 (B)
A critical issue in the management of pain in sickle cell
anemia is precisely which scale is most appropriate. An
assessment of the pain of 100 children with sickle cell anemia
and vaso-occlusive crisis using the three methods (African-
American Oucher scale, VAS and the Wong-Baker FACES scale)
showed that the FACES and Oucher scales were equally valid
and reliable as instruments to evaluate pain, but 56% of chil-
dren and adolescents preferred the FACES scale. The visual
analog scale had the lowest degree of reliability.37 (B)
A retrospective study of 3- to 21-year-old patients used the
VAS to compare 152 episodes of pain due to vaso-occlusion
in 77 patients with SCD versus 221 episodes of pain in 219
patients with long bone fracture. The pain scores were sig-
niﬁcantly higher in the children with painful vaso-occlusive
crisis (7.7 ± 2.5 vs. 6.7 ± 3.0; p-value = 0.005). In SCD patients,
there was no relationship between any pain assessment scale
and time to analgesic administration.38 (B)
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A retrospective study of 279 episodes of painful vaso-
cclusive crisis (initially treated with one dose of morphine)
n 105 over 8-year-old children with SCD found that appli-
ation of the Wong-Baker FACES pain scale (0–5) can guide
nalgesia management. The initial score was higher in hos-
italized compared to non-hospitalized children (4.4 vs. 3.9;
-value = 0.002). The FACES scale allowed a more  accurate
ssessment of the necessity of hospitalization in over 8-year-
ld SCD children with painful crisis who were being treated
ith morphine.39 (B)
A prospective study of 232 over 16-year-old SCD patients
ho  self-reported pain every day during six months using a
ain scale between 0 and 9, reported that the mean pain inten-
ity increased as the percentage of days with pain increased
p-value <0.001). Pain was reported on 56% of the total patient-
ays; pain crises without attending a medical service was
eported on 13% of the days and medical care was used only
n 3.5% of the days. About 30% of patients reported pain on
ore than 95% of the days. Based in the scale, the use of opi-
ids was higher on days with more  pain (p-value <0.001). Thus,
he pain scale also allows control of pain out of the hospital
ithout the indiscriminate use of opioids.40 (B)
The medication quantiﬁcation scale (MQS) associated with
 pain scale applied in 27 SCD children hospitalized for painful
risis, allows monitoring regarding the use of analgesics and
ain intensity. In this prospective study, 59.3% described the
nset of pain as sudden and that pain continued to be constant
or 70.4% of patients from the time of onset until admission
o the hospital. Using the African-American Oucher scale, the
ean score of pain intensity on the day of hospitalization was
4 ± 9.9 (range: 63.8–100), and the initial mean score of the MQS
as 15.7 ± 4.9 (range: 6–24). After drug therapy (morphine was
he most frequent), this score dropped 1.2 ± 0.5 points for each
ay of hospitalization (range: 0.9–2.5; p-value <0.0001). There
as a correlation between the pain level and drug dose; the
QS  proved to be a sensitive and useful tool to quantify the
tilization of analgesics in SCD.41 (B)
The pain level measured using the VAS (scores of 0–100)
n 74 SCD adults with vaso-occlusive crisis identiﬁed a mean
core of 80 [95% conﬁdence interval (CI): 75.99–82.95] on arrival
t hospital. The reduction in pain following the use of anal-
esics was monitored using the VAS. In patients reporting
 signiﬁcant improvement in pain, the change in the VAS
as 23.4 (95% CI: 15.4–31.4), while it was only 13.5 (95% CI:
1.25–15.74) in those in whom the improvement was minimal.
he study concluded that the minimum clinically signiﬁcant
core to assess improvement in pain during treatment with
nalgesia was 13.5; this also allows an evaluation of pain relief
n adults with SCD.42 (B)
A pain intensity scale (numeric rating scale) was used to
redict hospitalization of 65 patients aged between 13 and 53
ears old (mean: 23 years) with SCD and vaso-occlusive crisis
nd 80 acute events that resulted in 49 hospitalizations. The
ean initial score for pain was 8.5 in hospitalized patients
nd 5.1 for those who were discharged (p-value <0.001). When
onsidering a score of 6.5 as the cutoff point, the sensitivity
as 0.886 and speciﬁcity was 0.762, with positive and negative
redictive values of 0.886 and 0.760, respectively. Therefore,
he pain score allows an indication for hospitalization.43
B) 1 6;3  8(2):147–157 151
In the assessment of pain in 17 SCD children using the
FACES scale, the level of pain predicted the length of hospi-
talization. Children with a high score (>2) 24 h after receiving
medications spent more  time in hospital.44 (B)
Recommendation: The use of pain scales in SCD patients
with vaso-occlusive crisis can guide treatment, monitor
response and predict hospitalization.
What  is  the  best  sequence  of  medications  to
control  painful  vaso-occlusive  crisis?
P: Patients between 0 and 18 years old with sickle cell anemia
and painful crisis
I: Treatment with morphine versus meperidine
C: Treatment with paracetamol or dipyrone
O: Adequate pain control
The treatment of painful vaso-occlusive crisis in SCD
patients involves correcting triggering factors, such as
hypoxia, infection, acidosis, dehydration, physical exhaustion
and exposure to extreme cold. The management of painful cri-
sis is based on non-randomized clinical studies45,46 (A),47 (B),
and mainly consists of hydration and analgesia.48 (A) Thus,
many guidelines have been written to provide support in the
treatment of pain in sickle cell anemia.49,50 (D)
The proper use of analgesics is important and the prescrip-
tion should suit the intensity of pain, with a ﬁxed dose at
speciﬁc intervals, and not using medications ‘as necessary.’
The use of medications for pain management in over 12-
year-old children and adults should follow the three steps
of the analgesia scale (Table 2) recommended by the World
Health Organization (WHO)51,52 (D).
For under 12-year-old children, the use of drugs for the
management of pain is a little different because the analgesia
scale, as recommended by WHO  guidelines published in 2012,
has only two  steps (Table 3)53 (D).
The two-step approach considers the use of low doses of
strong opioid analgesics for the treatment of moderate pain
because it is not safe to use codeine in children due to prob-
lems related to genetic variability in biotransformation and
insufﬁcient data from clinical studies in children using other
intermediate opioids such as tramadol.53 (D)
Treatment of mild to moderate pain in over 12-year-old
children and adults should start with a non-opioid drug at
the recommended dose and frequency together with adjuvant
medications as necessary. If the pain does not stop, add a weak
opioid. If the weak opioid combined with a non-opioid drug
does not control the pain, the weak opioid should be replaced
by a strong opioid.48 (A)49,52 (D)
In under 12-year-old children with mild pain, treatment
should start with a non-opioid drug at the recommended dose
and frequency; if pain does not improve, a low dose of a strong
opioid should be added with the dose being increased only
if the pain does not improve. After a starting dose according
to the dosages recommended in Table 3, the dosage should
152  rev bras hematol hemoter. 2 0 1 6;3  8(2):147–157
Table 2 – Steps of pain management listed in the analgesia scale as recommended by the World Health Organization –
over 12-year-old children and adults51,52 (D).
Mild pain
Visual pain scale (1–4)
Moderate pain
Visual pain scale (5–7)
Severe  pain
Visual pain scale (8–10)
Non-opioid Weak opioid Strong opioid
Aspirin
30–60 mg/kg/day PO every 4 h
maximum 3.6 g/24 h
OR
Acetaminophen
10–15 mg/kg/dose PO every 4 h
maximum 635 mg/kg/day
OR
Dipyrone
5–10 mg/day PO every 4 h
Codeine
0.5–0.75 mg/kg/dose PO every 4 h
Codeine
0.75–1  mg/kg/dose IV or PO every
4 h
OR
Morphine
0.1–0.2 mg/kg IV or SC every 3 h or
4 h
OR
Tramadol
0.1–0.25 mg/kg/h IV
Ibuprofen
5–10 mg/kg PO every 6 h to 8 h
Tramadol
0.5 mg/kg IV
maximum 5 mg/kg/day every 6 h
PO: per os; IV: intravenous; SC: subcutaneous.
Table 3 – Steps of pain management listed in the
analgesia scale recommended by the World Health
Organization – under 12-year-old children53 (D).
Mild pain (non-opioid) Moderate/severe pain (strong opioid)
Acetaminophen
10–15 mg/kg/dose PO
every 4 h, maximum
635 mg/kg/day (WHO:
maximum 1 g each
dose) OR
Dipyrone
5–10 mg/day PO every
4 h OR
Ibuprofen
5–10 mg/kg PO every
6–8 h (max.
40 mg/kg/day)
Morphine
0.1–0.2 mg/kg IV or SC every 3 h or 4 h
PO: per os; IV: intravenous; SC: subcutaneous.
tent. The use of methylprednisolone should be avoided.
There is no indication for the administration of nitricbe adjusted to the level that is effective (with no maximum
dose). The maximum increase in dosage is 50% every 24 h in
outpatient settings.53 (D)
Do not use meperidine because, besides having one
tenth of the analgesic power of morphine, it is associated
with serious adverse events, such as seizures and physical
dependence.49,50,54,55 (D)
Intravenous morphine is considered the treatment of
choice for the severe pain crisis in sickle cell anemia, but
it is associated with several adverse events including acute
chest syndrome. Patient-controlled administration of mor-
phine compared to continuous use was no more  effective in
respect to pain management and length of hospital stay, but it
signiﬁcantly reduced opioid consumption and produced fewer
adverse events.56 (B)A randomized, double blind, parallel-group study com-
pared the use of oral versus continuous intravenous mor-
phine. Initial pain management used intravenous morphine
(up to 0.15 mg/kg). Subsequently, a comparison between oral
morphine (1.9 mg/kg every 12 h) and continuous intravenous
morphine (0.04 mg/kg/h) was made for the management of
pain episodes in sickle cell anemia patients; there was no dif-
ference in the resolution of pain nor the time of analgesic
administration. The need for rescue analgesia was similar, as
were the adverse effects. Oral morphine may be an alternative
to the use of continuous intravenous morphine.57 (B)
The use of oral or intravenous methylprednisone at a dose
of 15 mg/kg in two doses in the ﬁrst 24 h combined with mor-
phine can produce beneﬁts to reduce the time needed to
resolve pain in episodes of severe pain. However, the use of
corticosteroids is associated with a rebound effect with the
worsening of pain when its administration is stopped, and
its indication must be carefully considered.58 (B) The use of
corticosteroids favors painful crisis when used in acute chest
syndrome.59 (D)
The use of nitric oxide in the treatment of painful vaso-
occlusive crisis of hospitalized sickle cell anemia patients does
not shorten the time required for crisis resolution, does not
reduce the length of hospitalization, does not affect the inten-
sity of pain or chest pain, and does not reduce the use of
opioids.60 (A)
Recommendation: Pain management of vaso-occlusive
episodes in sickle cell anemia patients should be
designed according to the intensity of the pain. Oral or
intravenous morphine should be used in cases of severe
pain, with intravenous administration being intermit-oxide in this clinical situation.
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s  there  evidence  for  the  use  of  adjuvant
edications  such  as  non-steroidal
nti-inﬂammatory  drugs,  antihistamines,
ntidepressants,  benzodiazepines,
nticonvulsants  or  corticosteroids  in  the
anagement  of  painful  vaso-occlusive  crisis?
P: Patients between 0 and 18 years old with sickle cell anemia
and painful crisis
I: Treatment with non-steroidal anti-inﬂammatory drugs
(diclofenac, nimesulide, aspirin, COX 1 inhibitors and
COX 2 inhibitors), antihistamines, antidepressants, benzo-
diazepines and anticonvulsants
C: Treatment with paracetamol or dipyrone
O: Adequate pain control
There are few randomized clinical trials on the treatment
f the painful crisis in sickle cell anemia45 (A),46 (B), so that
ost of the treatment is based on data from non-randomized
tudies.49,55,61,62 (D)
Five studies with non-steroidal anti-inﬂammatory drugs
NSAIDs) as adjuvant pain medications for children and adults
ith SCD were reviewed. Oral diﬂunisal was similar to placebo.
wo studies with intravenous ketorolac in hospitalized adults
ere favorable to ketorolac for pain control, while two oth-
rs were not. The small sample sizes and the heterogeneity of
he methods preclude any conclusion in the use of NSAID to
reat pain in SCD and make any meta-analysis on this subject
nrealistic.45 (A) A phase III trial, double blind, randomized,
lacebo-controlled of 66 episodes of painful vaso-occlusive cri-
is concluded that ketorolac was not effective to control the
ain and the use of morphine when compared to a placebo.
he authors do not recommend the systematic use of ketoro-
ac in these patients.63 (A) No studies were found in the
iterature on other NSAIDs, such as acetaminophen.45 (A)
A double-blind randomized placebo-controlled study in
razil showed no beneﬁt with the use of piracetam in chil-
ren and young adults with sickle cell anemia and painful
aso-occlusive crisis in relation to the use of opioids, pain
ntensity and hospitalization.64 (A) Piracetam is ineffective in
he prevention of vaso-occlusive pain crisis.64 (A) These data
ere conﬁrmed in a meta-analysis with three studies, includ-
ng the Brazilian study, where it was concluded that there are
nsufﬁcient data to indicate piracetam for painful crisis in SCD
atients.65 (A)
Methylprednisolone or intravenous dexamethasone sug-
est beneﬁts in relation to pain management, but patients who
eceived a single dose of corticosteroids had a higher risk of
ain reactivation.45 (A)
Magnesium is a vasodilator that enhances the hydration of
ed blood cells. For this reason it was investigated in a random-
zed, double-blind, placebo-controlled study of 104 children
ith SCD hospitalized to receive intravenous analgesia for
ainful crisis. Intravenous magnesium sulfate had no effect
n reducing the length of hospital stay, improvements in pain
66r reductions in the cumulative dose of analgesics. (A)
Adjuvant medications have been used to enhance the anal-
esic effect of opioids in patients with cancer and to decrease
heir adverse events. Antihistamines (chlorpheniramine 1 6;3  8(2):147–157 153
0.15 mg/kg/day orally every 6 h with a maximum dose of
12 mg/day), antidepressants (amitriptyline 10–20 mg orally at
night), benzodiazepines (the dose depends on the benzodi-
azepine) and anticonvulsants (carbamazepine 5–10 mg/kg/day
once or twice a day) have mild analgesic effects. When indi-
cated, these medications should be used carefully.49,51,52 (D)
Recommendations: There is no consistent evidence sup-
porting the use of antidepressants, benzodiazepines and
anticonvulsants in the management of painful vaso-
occlusive crisis in sickle cell anemia. There are no
beneﬁts with piracetam or magnesium sulfate use in
painful vaso-occlusive crisis.
Is  there  evidence  for  the  use  of  oxygen  therapy
or  hyperhydration  in  the  management  of
painful  vaso-occlusive  crisis?
P: Patients between 0 and 18 years old with sickle cell anemia
and painful crisis
I: Treatment with oxygen therapy or hyperhydration
C: Treatment without oxygen therapy or hyperhydration
O: Adequate pain control
Although inhaled oxygen therapy (50% oxygen) in patients
with SCD reverses the sickling of red blood cells, there is no
evidence in the literature that its use in vaso-occlusive pain
crisis provides beneﬁts by reducing the pain, the use of opioids
or hospitalization.67,68 (B)
Dehydration is an important factor in the sickling process.
The decreased ability to concentrate urine, a characteristic
of SCD patients, results in inadequate control of hydration.
Thus, during painful crisis, patients receive intravenous or
oral hydration, regardless of their state of hydration. However,
care is necessary not to cause cardiac or pulmonary volume
overload. No randomized controlled trials report beneﬁts in
respect to improving or resolving pain with the infusion of
intravenous ﬂuids as adjuvant treatment in sickle cell anemia
patients with painful vaso-occlusive crisis, regardless of the
state of hydration.47 (A)
Hydration in patients with sickle cell anemia should be car-
ried out with caution. Hypotonic solutions may be used to
establish baseline hydration, maximum 1–1.5 times the main-
tenance volume including the medications volume.49,55,61,69,70
(D) Care should be taken to avoid excessive hydration because
it decreases the plasma oncotic pressure and increases the
hydrostatic pressure, with risk of pulmonary edema (espe-
cially in patients with kidney disease, heart disease or
previous lung disease).70 (D)
Recommendations: There is no published evidence on
the beneﬁts of oxygen therapy or excessive hydration in
sickle cell anemia patients with painful vaso-occlusive
crisis.
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Is  there  evidence  that  bone  scintigraphy  is  a
good  test  to  differentiate  the  painful
vaso-occlusive  crisis  from  osteomyelitis?  Is
there  any  test  that  allows  this  differentiation?
P: Patients between 0 and 18 years old with sickle cell anemia
and doubts between painful crisis and osteomyelitis
I: Bone scintigraphy
C: Clinical diagnosis
O: Differential diagnosis between painful vaso-occlusive cri-
sis and osteomyelitis
In sickle cell anemia, bone infarction is about 50 times more
common than osteomyelitis.71 (B) However, the differentia-
tion between osteomyelitis and bone infarction is difﬁcult. In
both situations the patient can have pain, fever, edema, ery-
thema, and leukocytosis and imaging tests (X-ray, computed
tomography) are nonspeciﬁc.72,73 (B)
A prospective study of 42 episodes of bone pain in children
with SCD showed that in most cases the diagnosis of bone
infarction is clinical. However, scintigraphy with technetium
can help in cases where there is doubt about osteomyelitis.
When bone marrow scintigraphy with technetium is made
within ten days of onset, the uptake is normal at the injury
site in the case of osteomyelitis (100% of cases) while in
bone infarction the uptake is diminished (93% of cases). Bone
scintigraphy with technetium has proven effective to identify
osteomyelitis in 100% of cases due to the higher uptake, but it
is not speciﬁc for bone infarction.74 (B)
Combination of sequential bone and bone marrow scintig-
raphy with technetium showed beneﬁts in the differential
diagnosis of bone infarction and osteomyelitis in 39 children
with SCD and bone pain. These exams should be performed
within 72 h of the onset of pain. Decreased bone marrow
uptake associated with normal or reduced bone uptake in
scintigraphy suggests a diagnosis of bone infarction, whereas
increased bone uptake suggests infection.75 (B)
Scintigraphy images of 79 children with SCD performed
within 24 h of the onset of pain were retrospectively analysed.
Bone marrow scintigraphy with technetium was performed
followed by bone scintigraphy. Reduced uptake by the bone
marrow and abnormal bone uptake suggested bone infarc-
tion and normal uptake by the bone marrow with increased
bone uptake suggested osteomyelitis. Seventy cases of bone
infarction were diagnosed with 66 being successfully treated
without antibiotics. Four cases were diagnosed as osteomyeli-
tis, in which three cultures were positive; no false negative
results were observed.73 (B)
A retrospective study of 22 episodes of suspected
osteomyelitis in SCD children showed that the combination
of bone scintigraphy with gallium and technetium can help in
the differential diagnosis of bone infarction and osteomyeli-
tis. The best data for diagnosis are obtained within 24 h after
the onset of symptoms.72 (B) The use of bone marrow scintig-
raphy with gallium and technetium was also effective for this
76differential diagnosis in a study of 18 episodes of pain. (C)
A prospective study of 53 SCD children with the need to
differentiate between vaso-occlusive crisis and osteomyeli-
tis found ultrasound changes of the soft tissue suggestive of 2 0 1 6;3  8(2):147–157
osteomyelitis in 17 patients; pus was drained from all patients.
The authors suggest that ultrasound should be considered as
the ﬁrst option to investigate osteomyelitis.77 (B) The over-
all sensitivity of soft tissue ultrasound in the diagnosis of
osteomyelitis was 74% with a speciﬁcity of 63%.78 (C) The ultra-
sound was normal in cases of bone infarction, and periosteal
elevation, subperiosteal or intramedullary abscesses and cor-
tical bone erosion can be observed in osteomyelitis.77 (B)78 (C)
The diagnosis of osteomyelitis by ultrasound can be enhanced
by investigating reactive protein C serum levels and leuko-
cyte counts, as these values are signiﬁcantly increased in
osteomyelitis.79 (B)
Magnetic resonance imaging (MRI) is a good imaging exam
to evaluate the bone marrow and to detect bone infarction.
However, in SCD, it is difﬁcult to differentiate between infarc-
tion and osteomyelitis with MRI.80 (D)
Although imaging tests can help to differentiate between
bone infarction and osteomyelitis, a clinical diagnosis is
always better.73,74,81 (B)
Recommendation: Differentiating bone infarction and
osteomyelitis remains a challenge because the clinical
presentation is similar in both cases and laboratory tests
are still of limited use. Bone scintigraphy with tech-
netium does not help to differentiate bone infarction in
sickle cell anemia patients with bone pain. Thus, the
combination of bone and bone marrow scintigraphy with
technetium can assist in the differentiation between
osteomyelitis and bone infarction, as can scintigraphy
using gallium and ultrasound of the soft tissues. MRI  may
play a role and be sought wherever possible in cases of
fever and prolonged pain.
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Appendix  A.
PICO 1
What  is the prevalence of sickle cell disease and how
are the results of neonatal screening for hemoglobinopathies
interpreted?
((Anemia, Hemolytic, Congenital AND screening
AND neonatal)) OR (((screening AND neonatal)) AND
(Hemoglobinopathies))
PICO 2
Is there evidence for the need to perform a conﬁrmatory
electrophoresis exam after the sixth month of life?
(Anemia, Sickle Cell OR Hemoglobinopathies OR
Hemoglobins) AND (Electrophoresis) AND (Neonatal OR
Newborn)
PICO 3
Is there evidence on the factors that cause vaso-occlusive
crisis?
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Sickle cell anemia AND (veno-occlusive disease OR veno-
cclusive syndrome OR pain OR vaso-occlusive OR vascular
isease OR crisis) AND (fever OR dehydration OR infection
R metabolic syndrome OR cold OR heat OR alcohol OR
steomyelitis OR cocaine OR marihuana OR etiology OR risk)
PICO 4
Is there evidence that the use of pain assessment scales
s a good method to monitor pain related to vaso-occlusive
risis?
Sickle cell anemia AND (veno-occlusive disease OR veno-
cclusive syndrome OR pain OR vaso-occlusive OR vascular
isease OR crisis) AND (Severity of Illness Index OR scale OR
core OR VAS OR measurement)
PICO 5
What  is the best sequence of medications to control painful
aso-occlusive crisis?
(Therapy/broad[ﬁlter] AND Sickle cell anemia AND (veno-
cclusive disease OR veno-occlusive syndrome OR pain OR
aso-occlusive OR vascular disease OR crisis))
PICO 6
Is there evidence for the use of adjuvant medications such
s non-steroidal anti-inﬂammatory drugs, antihistamines,
ntidepressants, benzodiazepines, anticonvulsants or cor-
icosteroids in the management of painful vaso-occlusive
risis?
(Therapy/broad[ﬁlter] OR anti-inﬂammatory OR Histamine
ntagonists OR anticonvulsant OR Benzodiazepines) AND
ickle cell anemia AND (veno-occlusive disease OR veno-
cclusive syndrome OR pain OR vaso-occlusive OR vascular
isease OR crisis)
PICO 7
Is there evidence for the use of oxygen therapy or hyperhy-
ration in the management of painful vaso-occlusive crisis?
Sickle cell anemia AND (veno-occlusive disease OR veno-
cclusive syndrome OR pain OR vaso-occlusive OR vascular
isease OR crisis) AND (oxygen therapy OR OXYGEN OR Fluid
herapy OR Infusions, Parenteral OR HYDRATION OR DEHY-
RATION)
PICO 8
Is there evidence that bone scintigraphy is a good test to
ifferentiate painful vaso-occlusive crisis from osteomyelitis?
s there any test that allows this differentiation?
((Radionuclide Imaging)) AND (sickle cell anemia)
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